Trial Outcomes & Findings for Adaptive Training Exercise Programs for Improving Cardiorespiratory Fitness After Breast Cancer Treatment, The ACTIVATE Trial (NCT NCT04667481)

NCT ID: NCT04667481

Last Updated: 2024-02-12

Results Overview

Will be determined with all-cause intervention discontinuation rate, which is the proportion of all intervention participants who permanently stop the intervention prior to week 24 for any reason.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

27 participants

Primary outcome timeframe

Week 24

Results posted on

2024-02-12

Participant Flow

Participant milestones

Participant milestones
Measure
Arm I (Aerobic Exercise)
Patients participate in AE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders participate in combined AE and RE sessions for an additional 12 weeks, while responders continue participating in the AE sessions alone for an additional 12 weeks. Aerobic Exercise Intervention: Participate in aerobic exercise intervention Resistance Exercise Intervention: Participate in resistance exercise intervention Quality-of-Life Assessment: Ancillary studies
Arm II (Resistance Exercise)
Patients participate in RE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders may participate in a further 12-weeks of combined AE and RE sessions, while responders continue participating in the RE sessions alone for an additional 12 weeks. Aerobic Exercise Intervention: Participate in aerobic exercise intervention Resistance Exercise Intervention: Participate in resistance exercise intervention Questionnaire Administration: Ancillary studies Quality-of-Life Assessment: Ancillary studies
Control Group (Digital Exercise Interventions)
After 24 weeks, patients receive a digital copy of the 12-week AE sessions and 12-week RE sessions and an outline of sessions for 24 weeks. Exercise Intervention: Digital copies and outline of sessions: Receive digital copy of AE and RE sessions and an outline of sessions Questionnaire Administration: Ancillary studies Quality-of-Life Assessment: Ancillary studies
Overall Study
STARTED
9
9
9
Overall Study
COMPLETED
9
8
8
Overall Study
NOT COMPLETED
0
1
1

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Adaptive Training Exercise Programs for Improving Cardiorespiratory Fitness After Breast Cancer Treatment, The ACTIVATE Trial

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Arm I (Aerobic Exercise)
n=9 Participants
Patients participate in AE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders participate in combined AE and RE sessions for an additional 12 weeks, while responders continue participating in the AE sessions alone for an additional 12 weeks. Aerobic Exercise Intervention: Participate in aerobic exercise intervention Resistance Exercise Intervention: Participate in resistance exercise intervention Quality-of-Life Assessment: Ancillary studies
Arm II (Resistance Exercise)
n=9 Participants
Patients participate in RE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders may participate in a further 12-weeks of combined AE and RE sessions, while responders continue participating in the RE sessions alone for an additional 12 weeks. Aerobic Exercise Intervention: Participate in aerobic exercise intervention Resistance Exercise Intervention: Participate in resistance exercise intervention Questionnaire Administration: Ancillary studies Quality-of-Life Assessment: Ancillary studies
Control Group (Digital Exercise Interventions)
n=9 Participants
After 24 weeks, patients receive a digital copy of the 12-week AE sessions and 12-week RE sessions and an outline of sessions for 24 weeks. Exercise Intervention: Digital copies and outline of sessions: Receive digital copy of AE and RE sessions and an outline of sessions Questionnaire Administration: Ancillary studies Quality-of-Life Assessment: Ancillary studies
Total
n=27 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Age, Categorical
Between 18 and 65 years
8 Participants
n=99 Participants
9 Participants
n=107 Participants
6 Participants
n=206 Participants
23 Participants
n=7 Participants
Age, Categorical
>=65 years
1 Participants
n=99 Participants
0 Participants
n=107 Participants
3 Participants
n=206 Participants
4 Participants
n=7 Participants
Age, Continuous
58.9 years
STANDARD_DEVIATION 5.7 • n=99 Participants
48.9 years
STANDARD_DEVIATION 11.7 • n=107 Participants
56.6 years
STANDARD_DEVIATION 11.6 • n=206 Participants
54.8 years
STANDARD_DEVIATION 10.6 • n=7 Participants
Sex: Female, Male
Female
9 Participants
n=99 Participants
9 Participants
n=107 Participants
9 Participants
n=206 Participants
27 Participants
n=7 Participants
Sex: Female, Male
Male
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
9 Participants
n=99 Participants
9 Participants
n=107 Participants
9 Participants
n=206 Participants
27 Participants
n=7 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
1 Participants
n=206 Participants
1 Participants
n=7 Participants
Race (NIH/OMB)
Asian
1 Participants
n=99 Participants
3 Participants
n=107 Participants
0 Participants
n=206 Participants
4 Participants
n=7 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
1 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
1 Participants
n=7 Participants
Race (NIH/OMB)
Black or African American
1 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
1 Participants
n=7 Participants
Race (NIH/OMB)
White
6 Participants
n=99 Participants
6 Participants
n=107 Participants
8 Participants
n=206 Participants
20 Participants
n=7 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants

PRIMARY outcome

Timeframe: Week 24

Will be determined with all-cause intervention discontinuation rate, which is the proportion of all intervention participants who permanently stop the intervention prior to week 24 for any reason.

Outcome measures

Outcome measures
Measure
Arm I: Aerobic Exercise
n=9 Participants
ARM I: Patients participate in aerobic exercise (AE) sessions 3 times per week for 12 weeks. After 12-weeks, non-responders participate in combined AE and resistance exercise (RE) sessions for an additional 12 weeks, while responders continue participating in the AE sessions alone for an additional 12 weeks.
Arm II: Resistance Exercise
n=9 Participants
ARM II: Patients participate in RE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders may participate in a further 12-weeks of combined AE and RE sessions, while responders continue participating in the RE sessions alone for an additional 12 weeks.
Control Group
After 24 weeks, patients receive a digital copy of the 12-week AE sessions and 12-week RE sessions and an outline of sessions for 24 weeks. Exercise Intervention: Digital copies and outline of sessions: Receive digital copy of AE and RE sessions and an outline of sessions Questionnaire Administration: Ancillary studies Quality-of-Life Assessment: Ancillary studies
Intervention Feasibility
Discontinued Intervention
1 Participants
3 Participants
Intervention Feasibility
Completed Intervention
8 Participants
6 Participants

SECONDARY outcome

Timeframe: Up to 24 weeks

Population: Only adverse events probably or definitely attributed to study procedures are counted.

Intervention safety will be determined by reviewing and quantifying the number of adverse events (mild, moderate, or severe), serious adverse events, and by reviewing the type and severity of adverse events attributed to study procedures among each study group.

Outcome measures

Outcome measures
Measure
Arm I: Aerobic Exercise
n=9 Participants
ARM I: Patients participate in aerobic exercise (AE) sessions 3 times per week for 12 weeks. After 12-weeks, non-responders participate in combined AE and resistance exercise (RE) sessions for an additional 12 weeks, while responders continue participating in the AE sessions alone for an additional 12 weeks.
Arm II: Resistance Exercise
n=9 Participants
ARM II: Patients participate in RE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders may participate in a further 12-weeks of combined AE and RE sessions, while responders continue participating in the RE sessions alone for an additional 12 weeks.
Control Group
n=9 Participants
After 24 weeks, patients receive a digital copy of the 12-week AE sessions and 12-week RE sessions and an outline of sessions for 24 weeks. Exercise Intervention: Digital copies and outline of sessions: Receive digital copy of AE and RE sessions and an outline of sessions Questionnaire Administration: Ancillary studies Quality-of-Life Assessment: Ancillary studies
Intervention Safety: Adverse Events
Count of participants with at least one AE
2 Participants
3 Participants
0 Participants
Intervention Safety: Adverse Events
Gastrointestinal/Digestive
0 Participants
0 Participants
0 Participants
Intervention Safety: Adverse Events
Respiratory
0 Participants
1 Participants
0 Participants
Intervention Safety: Adverse Events
Skin
0 Participants
0 Participants
0 Participants
Intervention Safety: Adverse Events
Musculoskeletal
2 Participants
3 Participants
0 Participants
Intervention Safety: Adverse Events
Nervous System/Neurological
0 Participants
0 Participants
0 Participants
Intervention Safety: Adverse Events
Psychiatric
0 Participants
0 Participants
0 Participants
Intervention Safety: Adverse Events
Injuries
1 Participants
2 Participants
0 Participants

SECONDARY outcome

Timeframe: Up to 24 weeks

Study feasibility will be measured by calculating recruitment rates (proportion of enrolled participants to all individuals approached), and loss to follow-up (proportion of participants who do not complete post-intervention assessments). A benchmark to determine feasibility is \< 40% loss to follow-up.

Outcome measures

Outcome measures
Measure
Arm I: Aerobic Exercise
n=27 Participants
ARM I: Patients participate in aerobic exercise (AE) sessions 3 times per week for 12 weeks. After 12-weeks, non-responders participate in combined AE and resistance exercise (RE) sessions for an additional 12 weeks, while responders continue participating in the AE sessions alone for an additional 12 weeks.
Arm II: Resistance Exercise
ARM II: Patients participate in RE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders may participate in a further 12-weeks of combined AE and RE sessions, while responders continue participating in the RE sessions alone for an additional 12 weeks.
Control Group
After 24 weeks, patients receive a digital copy of the 12-week AE sessions and 12-week RE sessions and an outline of sessions for 24 weeks. Exercise Intervention: Digital copies and outline of sessions: Receive digital copy of AE and RE sessions and an outline of sessions Questionnaire Administration: Ancillary studies Quality-of-Life Assessment: Ancillary studies
Study Feasibility
Did not complete endpoint assessment
2 Participants
Study Feasibility
Completed endpoint assessment
25 Participants

SECONDARY outcome

Timeframe: Up to 24 weeks

Acceptability will be measured with qualitative, open-ended to assess participant experience in the intervention and gather information for improving the protocol in future studies. Of particular attention will be the tolerability of a remote, home-based exercise intervention with a semi supervised format.

Outcome measures

Outcome measures
Measure
Arm I: Aerobic Exercise
n=9 Participants
ARM I: Patients participate in aerobic exercise (AE) sessions 3 times per week for 12 weeks. After 12-weeks, non-responders participate in combined AE and resistance exercise (RE) sessions for an additional 12 weeks, while responders continue participating in the AE sessions alone for an additional 12 weeks.
Arm II: Resistance Exercise
n=9 Participants
ARM II: Patients participate in RE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders may participate in a further 12-weeks of combined AE and RE sessions, while responders continue participating in the RE sessions alone for an additional 12 weeks.
Control Group
After 24 weeks, patients receive a digital copy of the 12-week AE sessions and 12-week RE sessions and an outline of sessions for 24 weeks. Exercise Intervention: Digital copies and outline of sessions: Receive digital copy of AE and RE sessions and an outline of sessions Questionnaire Administration: Ancillary studies Quality-of-Life Assessment: Ancillary studies
Intervention Acceptability
Satisfied with sessions
9 Participants
9 Participants
Intervention Acceptability
Exercise Provided Enough Challenge
9 Participants
9 Participants
Intervention Acceptability
Desired more personalized instruction
3 Participants
4 Participants

SECONDARY outcome

Timeframe: Up to 24 weeks

The Rating of Perceived Exertion (RPE) scale asks respondents to rate the intensity of exercise on a 1-10 scale, with higher values representing greater perceived exertion (1 = Very Light Activity, 10 = Maximum Possible Exertion). The measure has been validated for estimating both aerobic and resistance exercise exertion levels, providing a standard measure across intervention modalities. The average RPE for full-intensity sessions (the first few weeks involve an increasing RPE across sessions) will be calculated for each participant.

Outcome measures

Outcome measures
Measure
Arm I: Aerobic Exercise
n=9 Participants
ARM I: Patients participate in aerobic exercise (AE) sessions 3 times per week for 12 weeks. After 12-weeks, non-responders participate in combined AE and resistance exercise (RE) sessions for an additional 12 weeks, while responders continue participating in the AE sessions alone for an additional 12 weeks.
Arm II: Resistance Exercise
n=9 Participants
ARM II: Patients participate in RE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders may participate in a further 12-weeks of combined AE and RE sessions, while responders continue participating in the RE sessions alone for an additional 12 weeks.
Control Group
After 24 weeks, patients receive a digital copy of the 12-week AE sessions and 12-week RE sessions and an outline of sessions for 24 weeks. Exercise Intervention: Digital copies and outline of sessions: Receive digital copy of AE and RE sessions and an outline of sessions Questionnaire Administration: Ancillary studies Quality-of-Life Assessment: Ancillary studies
Intervention Session Intensity
5.86 units on a scale
Standard Deviation 1.37
5.60 units on a scale
Standard Deviation 1.62

SECONDARY outcome

Timeframe: Up to 24 weeks

Participants will complete an RPE rating after each session. These ratings will be used to calculate adherence rate for each participant. A session with an RPE that is at or above the intended RPE will be considered adherent. The number of adherent sessions will be divided by the total number of sessions, whether the session was attended or not. The participant adherence rates will be averaged to find a mean adherence rate per participant.

Outcome measures

Outcome measures
Measure
Arm I: Aerobic Exercise
n=9 Participants
ARM I: Patients participate in aerobic exercise (AE) sessions 3 times per week for 12 weeks. After 12-weeks, non-responders participate in combined AE and resistance exercise (RE) sessions for an additional 12 weeks, while responders continue participating in the AE sessions alone for an additional 12 weeks.
Arm II: Resistance Exercise
n=9 Participants
ARM II: Patients participate in RE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders may participate in a further 12-weeks of combined AE and RE sessions, while responders continue participating in the RE sessions alone for an additional 12 weeks.
Control Group
After 24 weeks, patients receive a digital copy of the 12-week AE sessions and 12-week RE sessions and an outline of sessions for 24 weeks. Exercise Intervention: Digital copies and outline of sessions: Receive digital copy of AE and RE sessions and an outline of sessions Questionnaire Administration: Ancillary studies Quality-of-Life Assessment: Ancillary studies
Intervention Adherence
52.8 percentage of adherent sessions
Standard Deviation 31.0
40.7 percentage of adherent sessions
Standard Deviation 32.2

OTHER_PRE_SPECIFIED outcome

Timeframe: Up to 24 weeks

This is operationalized as maximal exercise capacity, which is ascertained by measuring peak oxygen consumption (volume oxygen \[VO2\] peak) during cardiopulmonary exercise testing (CPET). All CPETs will be administered by a trained exercise physiologist using the Modified Bruce protocol, an appropriate testing paradigm for people with reduced physical functioning. This procedure will estimate the VO2 (absolute).

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Up to 24 weeks

This is operationalized as maximal exercise capacity, which is ascertained by measuring peak oxygen consumption (volume oxygen \[VO2\] peak) during cardiopulmonary exercise testing (CPET). All CPETs will be administered by a trained exercise physiologist using the Modified Bruce protocol, an appropriate testing paradigm for people with reduced physical functioning. This procedure will estimate the VO2 (relative to bodyweight).

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Up to 24 weeks

Submaximal exercise capacity, also considered functional capacity, will be determined with the six minute walk test (6MWT), which measures the distance a person can walk in six minutes (6MWD). A widely used measure of submaximal exercise capacity, the 6MWT will be administered at all study timepoints to evaluate intervention response.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Up to 24 weeks

Prior to the measurement of body weight, participants will be instructed to remove heavy clothing and empty pockets of their contents. Weight will be measured to the nearest one-tenth kg with a calibrated balance beam or digital scale.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Up to 24 weeks

Hip circumference will be measured to the nearest one-tenth cm.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Up to 24 weeks

Height will be measured while the participant stands without shoes using a wall-mounted stadiometer to the nearest one-tenth cm.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Up to 24 weeks

Subcutaneous (SQ) fat and visceral adipose tissue (VAT) will be assessed via abdominal MRI. For analysis, fat depots will be separated into abdominal SQ fat and VAT which will be further segmented into intraperitoneal (IP) and retroperitoneal (RP) fat using commercially available software. SQ fat will be defined as the fat outside the muscular abdominal wall; IP fat as fat within the mesentery and omentum bounded anteriorly and laterally by the abdominal wall and posteriorly by a curved line drawn between the kidneys; RP fat as the remaining fat. Adipose tissues will be segmented and colored from other tissues based on pixel intensity and known divisions of tissue planes. The MRI analyst, blinded to participant characteristics, will correct any misidentified fat or non-fat regions using manual tools provided within the software. To calculate each of the compartmental fat deposits, the number of subpixels within each fat compartment.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Up to 24 weeks

The ratio of thigh IMF to skeletal muscle (SM) will be ascertained via magnetic resonance imaging (MRI) by trained MRI technologists. Participants will undergo a screening process with the MRI technologist to ensure that eligibility criteria for MRI scans are met. Participants will then change into a hospital gown and enter the MRI scanner. In this longitudinal assessment of IMF, the MRI technologist will be instructed to match participant scan positions across time by matching the current scan position with the participant's previous scan position, recorded at the timepoint prior. MRI analysts will quantitate total and compartment amounts of muscle and adipose tissue using cross-sectional areas of thigh skeletal muscle (SM) and IMF using commercially available software. Thigh IMF area will be calculated as the number of fat pixels within the thigh musculature multiplied by the pixel surface area.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Up to 24 weeks

Waist circumference will be measured to the nearest one-tenth cm.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Up to 24 weeks

The Short Form Health Survey-36 (SF-36) is a widely used self-report measure of quality of life and health status. Comprised of 36 multiple choice questions, the SF-36 queries general perceptions a participant has about their health, as well as limitations to physical activity, physical health problems, mental health problems, pain, and energy/fatigue. The SF-36 is used across health research domains, and in breast cancer has been validated as a reliable longitudinal monitor of quality of life.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Up to 24 weeks

Time spent engaging in physical activity will be measured with the Physical Activity Recall Interview. The PAR assesses time spent in physical activity over the past 7 days.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Up to 24 weeks

Participants' perception of their current well-being will be assessed with the 28-item 5-point Likert scale Functional Assessment of Cancer Therapy (FACT)-General. The FACT-G contains 4 subscales measuring physical, social, emotional, and functional well-being and has been validated for reliably measuring well-being in cancer patients.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Up to 24 weeks

Time spent engaging in sedentary lifestyle behaviors will be measured with the self-administered Sedentary Behaviors Questionnaire (SBQ). The SBQ measures the minutes spent participating in 9 different sedentary behaviors per "typical" weekday and weekend day.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Up to 24 weeks

The Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale is a 13-item scale originally developed for and widely used to assess cancer-related fatigue. The FACIT-Fatigue scale measures severity (i.e., "I feel fatigued"; "I feel weak all over") and impact of fatigue (e.g., "I need help doing my usual activities"; "I have to limit my social activity because I am tired") over the past week, with responses scored on a 5-point scale, from 0 "not at all" to 4 "very much." The FACIT-Fatigue scale has excellent psychometric properties and a focus on physical aspects of fatigue.

Outcome measures

Outcome data not reported

Adverse Events

Arm I: Aerobic Exercise

Serious events: 0 serious events
Other events: 9 other events
Deaths: 0 deaths

Arm II: Resistance Exercise

Serious events: 0 serious events
Other events: 9 other events
Deaths: 0 deaths

Control Group

Serious events: 0 serious events
Other events: 9 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Arm I: Aerobic Exercise
n=9 participants at risk
ARM I: Patients participate in aerobic exercise (AE) sessions 3 times per week for 12 weeks. After 12-weeks, non-responders participate in combined AE and resistance exercise (RE) sessions for an additional 12 weeks, while responders continue participating in the AE sessions alone for an additional 12 weeks.
Arm II: Resistance Exercise
n=9 participants at risk
ARM II: Patients participate in RE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders may participate in a further 12-weeks of combined AE and RE sessions, while responders continue participating in the RE sessions alone for an additional 12 weeks.
Control Group
n=9 participants at risk
After 24 weeks, patients receive a digital copy of the 12-week AE sessions and 12-week RE sessions and an outline of sessions for 24 weeks. Exercise Intervention: Digital copies and outline of sessions: Receive digital copy of AE and RE sessions and an outline of sessions Questionnaire Administration: Ancillary studies Quality-of-Life Assessment: Ancillary studies
Gastrointestinal disorders
Any Gastrointestinal/Digestive
77.8%
7/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
66.7%
6/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
77.8%
7/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
Skin and subcutaneous tissue disorders
Any Skin
55.6%
5/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
55.6%
5/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
55.6%
5/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
Respiratory, thoracic and mediastinal disorders
Any Respiratory
66.7%
6/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
66.7%
6/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
33.3%
3/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
Musculoskeletal and connective tissue disorders
Any Musculoskeletal
100.0%
9/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
88.9%
8/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
88.9%
8/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
Nervous system disorders
Any Neurological
100.0%
9/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
100.0%
9/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
77.8%
7/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
Psychiatric disorders
Any Psychiatric
66.7%
6/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
55.6%
5/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
66.7%
6/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
Musculoskeletal and connective tissue disorders
Injury
77.8%
7/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
44.4%
4/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
22.2%
2/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms

Additional Information

Dr. Kerryn Reding, Study Principal Investigator

University of Washington

Phone: 206-221-1571

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place